Baxter BioPharma Solutions to manufacture Novavax COVID-19 vaccine
Manufacturing at Baxter's Halle/Westfalen, Germany facility will help increase commercial production and promote access in UK and European markets
Baxter BioPharma Solutions has agreed to provide sterile manufacturing services for NVX-CoV2373, Novavax’ COVID-19 recombinant nanoparticle vaccine candidate with Matrix-M adjuvant.
Novavax’ COVID-19 vaccine candidate is currently in Phase III trials and has not yet been authorized or approved for use.
In a bid to ensure the vaccine reaches patients if and when it receives approval, the Novavax/Baxter partnership will help to advance commercial-scale manufacturing, essential for the vaccine's production and distribution in the UK and European markets.
The contract manufacturer, which specialises in parenteral (injectable) pharmaceuticals, including vaccines, will operate from its state-of-the-art facility in Halle/Westfalen, Germany.
The recently expanded site has broad sterile manufacturing capabilities and areas of focus, offers current good manufacturing practices (cGMP) manufacturing with dedicated production areas and is designed to deliver products with optimum efficiency and speed-to-market.
According to Novavax, NVX-CoV2373 contains a full-length, prefusion spike protein made using Novavax’ recombinant nanoparticle technology and the company’s proprietary saponin-based Matrix-M adjuvant.
The purified protein is encoded by the genetic sequence of the SARS-CoV-2 spike (S) protein and is produced in insect cells.
It can neither cause COVID-19 disease nor can it replicate, is stable at 2–8 °C and is manufactured in a ready-to-use liquid formulation that permits distribution using standard vaccine supply chain channels.
“The quest to develop vaccines for COVID-19 has reinforced the opportunity for industry partners to work together and contribute their unique capabilities and expertise for the benefit of all,” said Marie Keeley, vice president, Baxter BioPharma Solutions.
Related News
-
News CBM secures funding from SK for C&G manufacturing expansion
SK's financial backing enables CBM to address significant capacity constraints in the cell and gene therapy manufacturing space -
News Lonza Switzerland site to undergo expansion of microbial development capabilities
The expansion includes the installation of a pilot suite with a 50-L fermenter and automation upgrades to accelerate clinical and commercial projects -
News PCI Pharma Services to build Clinical Supply Centre of Excellence in New England
The first-of-its-kind centre will offer biopharma clients convenience and efficiencies in the rapidly expanding Northeast -
News Early development demand continues to boost prospects for smaller CDMOs: CPhI Worldwide panel
The increasing outsourcing trend among pharmaceutical companies represents a promising opportunity for CDMOs. This panel discussion at CPhI Worldwide touched upon some of the opportunities, hurdles, and trends ahead for the CDMO market -
News Viral vector demand to flourish on wave of imminent approvals, CPhI Worldwide audience told
Expected increase in approvals for gene therapies, gene-modified cell therapies and recombinant vector vaccines will also increase pressure on manufacturers to build new capacity -
News BioProcess International webinar series to focus on optimising biologics manufacturing
Upcoming Late Stage Bioprocessing & Viral Vectors Digital Week running 2-11 November will address many goals and challenges associated with optimizing biologics manufacturing through different stages of the process -
News SGS completes expansion of its Biosafety Centre of Excellence in Glasgow
Clients to receive accelerated quality testing and reduced turnaround times -
News Catalent embarks on $230M viral vector expansion project at Harmans campus
By completion at the end of 2022, the campus will accommodate 18 cGMP viral vector manufacturing suites
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance